Cargando…
Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
To elucidate whether the pharmacokinetics (PK) and pharmacodynamics (PD) of sildenafil are influenced differently when it is coadministered with bosentan (S+B) or with ambrisentan (S+A), we evaluated the PK and PD profiles of sildenafil before and after 4–5 weeks of S+A or S+B treatment in patients...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351320/ https://www.ncbi.nlm.nih.gov/pubmed/26756977 http://dx.doi.org/10.1111/cts.12382 |
_version_ | 1782514754855632896 |
---|---|
author | Hakamata, A Odagiri, K Miyakawa, S Irisawa, H Takeuchi, K Inui, N Tanaka, S Uchida, S Watanabe, H |
author_facet | Hakamata, A Odagiri, K Miyakawa, S Irisawa, H Takeuchi, K Inui, N Tanaka, S Uchida, S Watanabe, H |
author_sort | Hakamata, A |
collection | PubMed |
description | To elucidate whether the pharmacokinetics (PK) and pharmacodynamics (PD) of sildenafil are influenced differently when it is coadministered with bosentan (S+B) or with ambrisentan (S+A), we evaluated the PK and PD profiles of sildenafil before and after 4–5 weeks of S+A or S+B treatment in patients with pulmonary arterial hypertension. The area under the plasma concentration–time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018). In the PD study, incremental shuttle walking distance was superior during treatment with S+A than during treatment with S+B (S+B; 280 m vs. S+A; 340 m, P = 0.042). There were no concerns about safety with either combination therapy regime. |
format | Online Article Text |
id | pubmed-5351320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53513202017-05-23 Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension Hakamata, A Odagiri, K Miyakawa, S Irisawa, H Takeuchi, K Inui, N Tanaka, S Uchida, S Watanabe, H Clin Transl Sci Research To elucidate whether the pharmacokinetics (PK) and pharmacodynamics (PD) of sildenafil are influenced differently when it is coadministered with bosentan (S+B) or with ambrisentan (S+A), we evaluated the PK and PD profiles of sildenafil before and after 4–5 weeks of S+A or S+B treatment in patients with pulmonary arterial hypertension. The area under the plasma concentration–time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018). In the PD study, incremental shuttle walking distance was superior during treatment with S+A than during treatment with S+B (S+B; 280 m vs. S+A; 340 m, P = 0.042). There were no concerns about safety with either combination therapy regime. John Wiley and Sons Inc. 2016-01-12 2016-02 /pmc/articles/PMC5351320/ /pubmed/26756977 http://dx.doi.org/10.1111/cts.12382 Text en © 2016 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Hakamata, A Odagiri, K Miyakawa, S Irisawa, H Takeuchi, K Inui, N Tanaka, S Uchida, S Watanabe, H Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension |
title | Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension |
title_full | Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension |
title_fullStr | Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension |
title_full_unstemmed | Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension |
title_short | Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension |
title_sort | pharmacokinetic and pharmacodynamic comparison of sildenafil‐bosentan and sildenafil‐ambrisentan combination therapies for pulmonary hypertension |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351320/ https://www.ncbi.nlm.nih.gov/pubmed/26756977 http://dx.doi.org/10.1111/cts.12382 |
work_keys_str_mv | AT hakamataa pharmacokineticandpharmacodynamiccomparisonofsildenafilbosentanandsildenafilambrisentancombinationtherapiesforpulmonaryhypertension AT odagirik pharmacokineticandpharmacodynamiccomparisonofsildenafilbosentanandsildenafilambrisentancombinationtherapiesforpulmonaryhypertension AT miyakawas pharmacokineticandpharmacodynamiccomparisonofsildenafilbosentanandsildenafilambrisentancombinationtherapiesforpulmonaryhypertension AT irisawah pharmacokineticandpharmacodynamiccomparisonofsildenafilbosentanandsildenafilambrisentancombinationtherapiesforpulmonaryhypertension AT takeuchik pharmacokineticandpharmacodynamiccomparisonofsildenafilbosentanandsildenafilambrisentancombinationtherapiesforpulmonaryhypertension AT inuin pharmacokineticandpharmacodynamiccomparisonofsildenafilbosentanandsildenafilambrisentancombinationtherapiesforpulmonaryhypertension AT tanakas pharmacokineticandpharmacodynamiccomparisonofsildenafilbosentanandsildenafilambrisentancombinationtherapiesforpulmonaryhypertension AT uchidas pharmacokineticandpharmacodynamiccomparisonofsildenafilbosentanandsildenafilambrisentancombinationtherapiesforpulmonaryhypertension AT watanabeh pharmacokineticandpharmacodynamiccomparisonofsildenafilbosentanandsildenafilambrisentancombinationtherapiesforpulmonaryhypertension |